MEDirect Latino Inc. Reports 60% Increase in Customer Response for Puerto Rico Market in June

MEDirect Latino Inc. (OTC:MLTO) - 
http://www.medirectlatino.org - today, reported a 60 percent increase
over projected customer response rate for its media campaign focused
on Medicare eligible direct to consumer diabetic customers in Puerto
Rico in the month of June 2005.
   The Company has implemented additional infrastructure and hired
additional Diabetic Customer Care Specialists to handle added volume
of sales resulting from the Company's increasing focus on the Puerto
Rico Market. Sales of the Company's proprietary branded line of
Dialogistic Testing supplies increased 78% over the previous month's
results.
   The Company anticipated an increase of sales as a result of the
comprehensive media rollout, and worked directly with pharmaceutical
suppliers and manufactures to maintain sufficient product inventory
levels to meet the customer demands. MEDirect Latino maintains
just-in-time inventory controls which compliments the Medicare
reimbursable model. The Company's distribution center, at full
capacity, can process 5000 customer orders weekly.
   Based upon the customer demand, which has exceeded the Company's
projections, MEDirect Latino is anticipating generating gross revenues
of $10,190,956 within the next 12 months and EBITDA of approximately
$3,000,000.
   MEDirect Latino is a rapidly growing, 3-year-old, federally
licensed national provider of direct-to-consumer Medicare reimbursed
medical products focused exclusively on chronic diseases afflicting
the Hispanic community in the United States and Puerto Rico. MEDirect
is uniquely positioned to serve the U.S. Hispanic healthcare market as
a direct-to-consumer Medicare provider.
   In discussing the success of the campaign in Puerto Rico, Chief
Operating Officer of MLTO, Mr. Charles W. Hansen III, stated: "We can
now confirm our anticipated customer response results with true
numbers of calls received and customers closed during June's media
campaign and they have far exceeded our expectations. In closing,
Management has a comfort level with our expectations for our national
media rollout with the networks of Univision and Telemundo in July."

   About MEDirect Latino:

   MEDirect Latino (OTC:MLTO) - http://www.medirectlatino.org - is a
rapidly growing, uniquely positioned provider of direct-to-consumer
Medicare reimbursed medical products focused exclusively on chronic
diseases afflicting the Hispanic community in the United States and
Puerto Rico. MEDirect is the only company positioned to serve the U.S.
Hispanic healthcare market as a direct-to-consumer Medicare provider
on an authentically national level. The Company's current focus is the
distribution of products for the treatment of Type II diabetes
specifically because of its disproportionate impact and increasing
diagnosis rate within the US Hispanic population, noting an incidence
of 120% higher than among non-Hispanic whites. Type II diabetes was
also targeted because of its unique status within the Medicare
reimbursement regime and because of its high degree of correlation to
other chronic conditions such as high blood pressure and heart
disease. These other conditions represent considerable future market
potential that will allow MEDirect to efficiently scale its model by
leveraging its existing client base and infrastructure.
   The current Hispanic market for MEDirect's products is
conservatively estimated at approximately $650MM in the continental
United States. The size of the opportunity is understated by such
figures as an estimated 925,000 of the over 3.1 million Hispanics in
the United States over 65 eligible to receive Medicare benefits are
currently collecting these benefits with an estimate that over 1.4
million of those Medicare-eligible Hispanics have diabetes (implying a
potential continental U.S. market for MEDirect products of
approximately $1 billion).

   Forward-Looking Statements:

   Statements about the Company's future expectations, including
future revenues and earnings, and all other statements in this press
release other than historical facts are "forward-looking statements"
within the meaning of section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934, and as the term is
defined in the Private Litigation Reform Act of 1995. The Company's
actual results could differ materially from expected results. The
Company undertakes no obligation to update forward-looking statements
to reflect subsequently occurring events or circumstances. Should
events occur which materially affect any comments made within this
press release, the Company will appropriately inform the public.